- Tel: 858.663.9055
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
KRT1 (Keratin 1), also known as Cytokeratin 1, is a key structural protein of suprabasal keratinocytes in stratified squamous epithelium, where it plays a central role in epidermal differentiation and barrier formation. A KRT1 antibody is widely used in research to evaluate keratinocyte maturation, characterize epidermal organization, and investigate differentiation-dependent changes in epithelial tissues.
KRT1 antibody, also referred to as Keratin 1 antibody or CK1 antibody, is particularly valuable for studying suprabasal epithelial layers in skin and other stratified epithelia. Its expression is tightly linked to terminal differentiation, making it an important marker for distinguishing mature keratinocytes from basal and progenitor cell populations.
KRT1 is a type II cytokeratin that forms obligate heterodimers with keratin 10 (KRT10), creating intermediate filament networks that provide mechanical stability to differentiated keratinocytes. Its expression is primarily restricted to suprabasal layers of the epidermis and other keratinized epithelia, where it supports structural integrity and contributes to the formation of the skin barrier.
Unlike basal keratins such as Cytokeratin 14, which are expressed in proliferative keratinocytes, KRT1 is upregulated as cells exit the cell cycle and undergo terminal differentiation. This transition from basal to suprabasal keratin expression reflects a key step in epidermal maturation, making KRT1 a reliable indicator of differentiated epithelial states.
KRT1 is widely studied in dermatological and epithelial biology research due to its role in keratinocyte differentiation and epidermal homeostasis. Alterations in KRT1 expression are associated with disorders of keratinization and abnormal epithelial differentiation, making it a useful marker for investigating skin diseases and epithelial dysfunction.
In cancer research, KRT1 expression is typically retained in well-differentiated squamous epithelia and may be reduced or altered in poorly differentiated tumors. As such, it can provide insight into tumor differentiation status and epithelial maturation within squamous cell carcinomas and related malignancies.
A KRT1 antibody is commonly used to assess epithelial differentiation and stratification across a variety of experimental systems. In immunohistochemistry, it enables visualization of suprabasal keratinocyte layers and differentiation gradients within stratified epithelia. In western blot and related assays, it supports detection of differentiation-associated keratin expression in epithelial cells and tissues.
Because of its restricted expression pattern and strong association with terminal differentiation, KRT1 antibody reagents are particularly useful for distinguishing mature epithelial cells from basal and proliferative compartments.
KRT1 is part of a coordinated keratin expression program that reflects epithelial differentiation status. It is closely associated with keratin 10 (KRT10) in suprabasal layers, while basal keratins such as Cytokeratin 14 and Cytokeratin 5 define proliferative epithelial compartments. In contrast to markers such as Cytokeratin 19 and Cytokeratin 18, which are associated with simple and glandular epithelia, KRT1 is specific to stratified squamous epithelial differentiation.
This complementary expression pattern makes KRT1 antibody an important component of cytokeratin panels used to evaluate epithelial maturation and tissue organization.
For immunohistochemistry-based analysis of suprabasal epithelial differentiation, explore our Cytokeratin 1 Antibody for IHC, which is validated for staining of stratified epithelial tissues and supports reliable detection of differentiated keratinocyte populations.
This KRT1 antibody page is part of a broader KRT antibody panel used to study epithelial differentiation, tissue distribution, and tumor classification across multiple keratin family members.
IHC staining of FFPE human skin tissue with KRT1 antibody (clone LHK1).